vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.
Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $7.6M, roughly 1.1× Marygold Companies, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -766.0%, a 758.5% gap on every dollar of revenue. On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -79.3%). Over the past eight quarters, Marygold Companies, Inc.'s revenue compounded faster (-1.5% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
ACLX vs MGLD — Head-to-Head
Income Statement — Q1 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $7.6M |
| Net Profit | $-62.3M | $-576.0K |
| Gross Margin | — | 74.0% |
| Operating Margin | -847.6% | -8.3% |
| Net Margin | -766.0% | -7.5% |
| Revenue YoY | -79.3% | -4.5% |
| Net Profit YoY | -765.1% | 67.0% |
| EPS (diluted) | $-1.13 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $7.2M | ||
| Q1 25 | $8.1M | $7.0M | ||
| Q4 24 | $15.3M | $8.0M | ||
| Q3 24 | $26.0M | $7.9M | ||
| Q2 24 | $27.4M | $8.3M | ||
| Q1 24 | $39.3M | $7.9M |
| Q4 25 | — | $-576.0K | ||
| Q3 25 | — | $-356.0K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | $-62.3M | $-1.0M | ||
| Q4 24 | $-47.1M | $-1.7M | ||
| Q3 24 | $-25.9M | $-1.6M | ||
| Q2 24 | $-27.2M | $-1.9M | ||
| Q1 24 | $-7.2M | $-529.0K |
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 70.5% |
| Q4 25 | — | -8.3% | ||
| Q3 25 | — | -18.2% | ||
| Q2 25 | — | -16.5% | ||
| Q1 25 | -847.6% | -21.4% | ||
| Q4 24 | -348.2% | -22.8% | ||
| Q3 24 | -129.1% | -27.4% | ||
| Q2 24 | -127.8% | -33.3% | ||
| Q1 24 | -40.3% | -18.7% |
| Q4 25 | — | -7.5% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | -20.4% | ||
| Q1 25 | -766.0% | -14.4% | ||
| Q4 24 | -308.4% | -21.8% | ||
| Q3 24 | -99.4% | -20.1% | ||
| Q2 24 | -99.3% | -22.5% | ||
| Q1 24 | -18.3% | -6.7% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | $-1.13 | $-0.02 | ||
| Q4 24 | $-0.87 | $-0.04 | ||
| Q3 24 | $-0.48 | $-0.04 | ||
| Q2 24 | $-0.51 | $-0.05 | ||
| Q1 24 | $-0.14 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $22.7M |
| Total Assets | $648.1M | $27.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | $543.3M | $15.6M | ||
| Q4 24 | $587.4M | $14.9M | ||
| Q3 24 | $574.3M | $17.5M | ||
| Q2 24 | $516.7M | $15.0M | ||
| Q1 24 | $573.9M | $16.1M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $22.9M | ||
| Q2 25 | — | $23.0M | ||
| Q1 25 | $416.9M | $24.3M | ||
| Q4 24 | $454.8M | $23.4M | ||
| Q3 24 | $483.0M | $25.5M | ||
| Q2 24 | $487.2M | $26.6M | ||
| Q1 24 | $496.6M | $28.4M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | $648.1M | $33.5M | ||
| Q4 24 | $711.3M | $33.0M | ||
| Q3 24 | $764.9M | $35.9M | ||
| Q2 24 | $734.3M | $32.9M | ||
| Q1 24 | $779.7M | $33.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-908.0K |
| Free Cash FlowOCF − Capex | $-63.9M | — |
| FCF MarginFCF / Revenue | -786.4% | — |
| Capex IntensityCapex / Revenue | 9.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-908.0K | ||
| Q3 25 | — | $-533.0K | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | $-63.1M | $-1.2M | ||
| Q4 24 | $-46.0M | $-770.0K | ||
| Q3 24 | $30.7M | $-893.0K | ||
| Q2 24 | $-36.2M | $-1.9M | ||
| Q1 24 | $-31.9M | $-658.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | $-776.0K | ||
| Q3 24 | $28.4M | $-940.0K | ||
| Q2 24 | $-39.5M | $-2.0M | ||
| Q1 24 | $-38.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -46.8% | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | -9.7% | ||
| Q3 24 | 109.2% | -11.9% | ||
| Q2 24 | -144.1% | -23.8% | ||
| Q1 24 | -97.7% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | 9.6% | 0.0% | ||
| Q4 24 | 9.8% | 0.1% | ||
| Q3 24 | 8.8% | 0.6% | ||
| Q2 24 | 11.7% | 0.7% | ||
| Q1 24 | 16.4% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
